265 related articles for article (PubMed ID: 19220274)
1. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.
Devold HM; Molden E; Skurtveit S; Furu K
Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Bakhai A; Rigney U; Hollis S; Emmas C
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
[TBL] [Abstract][Full Text] [Related]
3. Switching statins in Norway after new reimbursement policy: a nationwide prescription study.
Sakshaug S; Furu K; Karlstad Ø; Rønning M; Skurtveit S
Br J Clin Pharmacol; 2007 Oct; 64(4):476-81. PubMed ID: 17441934
[TBL] [Abstract][Full Text] [Related]
4. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.
Tirkkonen T; Ryynänen A; Vahlberg T; Irjala K; Klaukka T; Huupponen R; Laine K
Drug Saf; 2008; 31(3):231-40. PubMed ID: 18302447
[TBL] [Abstract][Full Text] [Related]
5. Statin medication in patients treated with antiepileptic drugs in Norway.
Gedde-Dahl A; Devold HM; Molden E
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):881-5. PubMed ID: 22529023
[TBL] [Abstract][Full Text] [Related]
6. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Molden E; Skovlund E; Braathen P
Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
Milner E; Ainsworth M; Gleaton M; Bookstaver D
J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
[TBL] [Abstract][Full Text] [Related]
9. Co-medication of statins with contraindicated drugs.
Yang BR; Seong JM; Choi NK; Shin JY; Lee J; Kim YJ; Kim MS; Park S; Song HJ; Park BJ
PLoS One; 2015; 10(5):e0125180. PubMed ID: 25932626
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
[TBL] [Abstract][Full Text] [Related]
11. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal choices and dosing of statins at start of therapy.
Mantel-Teeuwisse AK; Klungel OH; Schalekamp T; Verschuren WM; Porsius AJ; de Boer A
Br J Clin Pharmacol; 2005 Jul; 60(1):83-9. PubMed ID: 15963098
[TBL] [Abstract][Full Text] [Related]
14. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
Hartz I; Sakshaug S; Furu K; Engeland A; Eggen AE; Njølstad I; Skurtveit S
BMC Clin Pharmacol; 2007 Dec; 7():14. PubMed ID: 18053228
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
16. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study.
Einarson TR; Metge CJ; Iskedjian M; Mukherjee J
Clin Ther; 2002 Dec; 24(12):2126-36. PubMed ID: 12581550
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
18. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
19. The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013.
Fuksa L; Vocelka M; Vytrisalova M
Health Policy; 2015 Sep; 119(9):1255-64. PubMed ID: 25929214
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
